Abstract:Background The Inflammatory Bowel Diseases (IBD) are chronic inflammatory disorders of the gastrointestinal tract and are associated with changes in intestinal epithelial barrier function. However, despite several effective therapeutic options, many patients become refractory to the treatment and adverse effects have been reported. For this reason, the development of new drugs targeting the epithelial barrier function is essential. Recently, polysaccharides isolated from plants and fungi have emerged as an important class of natural products with immunomodulatory, anti‐inflammatory and wound healing activity. Previous studies showed that rhamnogalacturonan (RGal), a polysaccharide isolated from Acmella oleracea , protected mice against colitis induced by dextran sulfate sodium (DSS). However, the exact mechanism of action of RGal are not fully clarified. We hypothesized that RGal modulates the intestinal epithelial barrier function and assessed the signaling pathways involved in RGal effect. Methods Human colonic epithelial Caco‐2 cells were seeded on Snapwells, grown for 6 days, and mounted in Ussing chambers to measure the epithelial barrier function [transepithelial electrical resistance (TER) and FITC‐dextran permeability]. Cells were apically treated with RGal (10–1000 μg/ml) after 30 min of FITC‐dextran addition. In a calcium‐switch assay, the epithelial monolayers were temporarily exposed to zero calcium conditions (calcium‐free buffer containing the calcium chelator, EGTA) to disassemble tight junctions. RGal (10–1000 μg/ml) was added during calcium‐free conditions. The FITC‐dextran permeability was also evaluated in Caco‐2 cells stimulated with IFNg plus TNF‐a (25 ng/ml, basolateral) and treated with RGal (1000 μg/ml, apical) every 24 h for 48 h. To evaluate the signaling pathways, the cells were pre‐treated with selective inhibitors of MEK1/2, p38 or PI3K 30 minutes before RGal addition. Results Apical addition of RGal at concentration of 1000 μg/ml significantly increased TER in 185% and caused a 64% reduction in FITC‐dextran flux compared to control group. In addition, RGal also was able to accelerate the tight junction reassembly in 155% during a reversible barrier disruption induced by calcium depletion. When the barrier disruption was caused by cytokines, RGal (1000 μg/ml) significantly reduced the FITC‐dextran flux by 33 and 24% at 30 and 60 min, respectively. However, the signaling pathway inhibitors did not reverse the RGal effect on TER suggesting that MAPkinase and PI3K pathways were not involved. Conclusions These findings demonstrated that RGal increases intestinal epithelial barrier function which appears to be due to effects on tight junction assembly. Further experiments will be carried out to determine the tight junction proteins and signaling pathways are involved in the RGal effect. Elucidation of RGal mechanisms of action could lead to new approaches to the treatment of IBD. Support or Funding Information Dr. Baggio is supported by an Eyes High postdoctoral fellowship from the University of Calgary. Her research project is funded by a grant from Crohn's and Colitis Canada.

GelNB molecular coating as a biophysical barrier to isolate intestinal irritating metabolites and regulate intestinal microbial homeostasis in the treatment of inflammatory bowel disease

An olsalazine nanoneedle-embedded inulin hydrogel reshapes intestinal homeostasis in inflammatory bowel disease

Colon‐Targeted Adhesive Hydrogel Microsphere for Regulation of Gut Immunity and Flora

Lactobacillus rhamnosus GG coating with nanocomposite ameliorates intestinal inflammation

W-GA nanodots restore intestinal barrier functions by regulating flora disturbance and relieving excessive oxidative stress to alleviate colitis

Pathologically catalyzed physical coating restores the intestinal barrier for inflammatory bowel disease therapy

Oral Delivery of Bioactive Glass-Loaded Core-Shell Hydrogel Microspheres for Effective Treatment of Inflammatory Bowel Disease

Restore Intestinal Barrier Integrity: An Approach for Inflammatory Bowel Disease Therapy

Ternary inulin hydrogel with long-term intestinal retention for simultaneously reversing IBD and its fibrotic complication

Metabolic Nanoregulator Remodels Gut Microenvironment for Treatment of Inflammatory Bowel Disease

Orally administrated liquid metal agents for inflammation-targeted alleviation of inflammatory bowel diseases

Cell membrane nanomaterials composed of phospholipids and glycoproteins for drug delivery in inflammatory bowel disease: A review

pH-responsive CuS/DSF/EL/PVP nanoplatform alleviates inflammatory bowel disease in mice via regulating gut immunity and microbiota

Closed-loop theranostic microgels for immune microenvironment modulation and microbiota remodeling in ulcerative colitis

Bioorthogonal conjugation and responsive nanocoating of probiotics for inflammatory bowel disease

ROS Scavenging and inflammation-directed polydopamine nanoparticles regulate gut immunity and flora therapy in inflammatory bowel disease

A Gas Therapy Strategy for Intestinal Flora Regulation and Colitis Treatment by Nanogel‐based Multistage NO Delivery Microcapsules

Oral hydrogel nanoemulsion co-delivery system treats inflammatory bowel disease via anti-inflammatory and promoting intestinal mucosa repair

Engineered probiotics with sustained release of interleukin-2 for the treatment of inflammatory bowel disease after oral delivery

Recent progress on engineered micro/nanomaterials mediated modulation of gut microbiota for treating inflammatory bowel disease

Modulation of Intestinal Epithelial Barrier Function by Rhamnogalacturonan